With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Solara Active Pharma Sciences (NSE:SOLARA). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
Solara Active Pharma Sciences' Improving Profits
In business, profits are a key measure of success; and share prices tend to reflect earnings per share (EPS) performance. So for many budding investors, improving EPS is considered a good sign. It's an outstanding feat for Solara Active Pharma Sciences to have grown EPS from ₹1.95 to ₹7.66 in just one year. Even though that growth rate may not be repeated, that looks like a breakout improvement. This could point to the business hitting a point of inflection.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Solara Active Pharma Sciences remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 27% to ₹15b. That's progress.
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
See our latest analysis for Solara Active Pharma Sciences
While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Solara Active Pharma Sciences' balance sheet strength, before getting too excited.
Are Solara Active Pharma Sciences Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Solara Active Pharma Sciences insiders have a significant amount of capital invested in the stock. Indeed, they hold ₹2.9b worth of its stock. That shows significant buy-in, and may indicate conviction in the business strategy. Those holdings account for over 9.9% of the company; visible skin in the game.
Does Solara Active Pharma Sciences Deserve A Spot On Your Watchlist?
Solara Active Pharma Sciences' earnings per share growth have been climbing higher at an appreciable rate. That EPS growth certainly is attention grabbing, and the large insider ownership only serves to further stoke our interest. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So at the surface level, Solara Active Pharma Sciences is worth putting on your watchlist; after all, shareholders do well when the market underestimates fast growing companies. You should always think about risks though. Case in point, we've spotted 2 warning signs for Solara Active Pharma Sciences you should be aware of.
Although Solara Active Pharma Sciences certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Indian companies that not only boast of strong growth but have strong insider backing.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.